Andrew J. Rae
Director/Board Member chez University of British Columbia
Profil
Andrew J.
Rae was the founder of iCo Therapeutics, Inc. founded in 2005, where he held the titles of President, Chief Executive Officer & Director until 2020.
He is currently a Director at the University of British Columbia.
Mr. Rae has an MBA from Simon Fraser University and an undergraduate degree from the University of Western Ontario.
Postes actifs de Andrew J. Rae
| Sociétés | Poste | Début |
|---|---|---|
| University of British Columbia | Director/Board Member | 02/11/2010 |
Anciens postes connus de Andrew J. Rae
| Sociétés | Poste | Fin |
|---|---|---|
| SATELLOS BIOSCIENCE INC. | Founder | 09/03/2020 |
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Director/Board Member | 24/03/2010 |
| Liponex, Inc. | Director/Board Member | 15/08/2007 |
Ability Biomedical Corp.
 Ability Biomedical Corp. Miscellaneous Commercial ServicesCommercial Services Part of Bristol Myers Squibb Co., Ability Biomedical Corp. is a Canadian company that researches and develops chemokine-based therapeutics. The private company is based in Vancouver, Canada. Ability Biomedical was acquired by Medarex, Inc., part of Bristol Myers Squibb Co. from September 01, 2009 on August 05, 2004 for $8.43 million. | Director of Finance/CFO | 01/08/2004 |
| GLOBAL GAMING TECHNOLOGIES CORP. | Director/Board Member | - |
Formation de Andrew J. Rae
| Simon Fraser University | Masters Business Admin |
| University of Western Ontario | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GLOBAL GAMING TECHNOLOGIES CORP. | Finance |
| Entreprise privées | 6 |
|---|---|
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |
| Liponex, Inc. | Health Technology |
Ability Biomedical Corp.
Ability Biomedical Corp. Miscellaneous Commercial ServicesCommercial Services Part of Bristol Myers Squibb Co., Ability Biomedical Corp. is a Canadian company that researches and develops chemokine-based therapeutics. The private company is based in Vancouver, Canada. Ability Biomedical was acquired by Medarex, Inc., part of Bristol Myers Squibb Co. from September 01, 2009 on August 05, 2004 for $8.43 million. | Commercial Services |
Active Pass Pharmaceuticals, Inc.
 Active Pass Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Active Pass Pharmaceuticals, Inc. develops drugs for infectious diseases. It engages in the development of drugs that inhibit ABC transporters. The firm also provides portfolio of therapeutic programs, including age-related macular degeneration, travelers' diarrhea, and lipid disorders. The company was founded by Peter B Reiner in 1998 and is headquartered in Vancouver, Canada. | Health Technology |
iCo Therapeutics, Inc.
 iCo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology iCo Therapeutics, Inc. is a canadian biotechnology company. It engages in the business of identification, development and commercialization of drug candidates to treat ocular and infectious diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA. | Health Technology |
Covenant House Vancouver
 Covenant House Vancouver Services to the Health IndustryHealth Services Covenant House Vancouver provides shelter and services to children and youth. It offers homeless, runaway and at-risk youth between the ages of 16 and 24 with short-term residential care through its crisis program. The company was founded on September 22, 1997 and is headquartered in Vancouver, Canada. | Health Services |
